-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 24, NMPA's official website showed that Chengdu Better Pharmaceutical's calcium gluconate injection passed the consistency evaluation of generic drugs, which was the first domestic review
.
Calcium gluconate injection is a commonly used calcium supplement in clinical practice, with terminal sales of over 600 million yuan in Chinese public medical institutions in 2020
.
.
Calcium gluconate injection is a commonly used calcium supplement in clinical practice, with terminal sales of over 600 million yuan in Chinese public medical institutions in 2020
.
Calcium gluconate injection is a commonly used intravenous calcium supplementation drug in clinical practice.
It is suitable for the treatment of calcium deficiency, acute hypocalcemia, alkalosis and tetany caused by hypoparathyroidism
.
It is suitable for the treatment of calcium deficiency, acute hypocalcemia, alkalosis and tetany caused by hypoparathyroidism
.
According to data from Minet.
com, in 2020, the sales of terminal calcium gluconate injection in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 600 million yuan; its sales in the first half of 2021 More than 300 million yuan, a year-on-year increase of 26.
20%
.
com, in 2020, the sales of terminal calcium gluconate injection in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 600 million yuan; its sales in the first half of 2021 More than 300 million yuan, a year-on-year increase of 26.
20%
.
Sales of terminal calcium gluconate injection in Chinese public medical institutions (unit: ten thousand yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
As the main manufacturer of calcium gluconate injection, the market share of this product in Chengdu Bite Pharmaceutical continued to increase.
In 2016, the market share was only 0.
04%, and in the first half of 2021, it has risen to 17.
38%
.
In 2016, the market share was only 0.
04%, and in the first half of 2021, it has risen to 17.
38%
.
At present, a total of 50 domestic companies have the production approval for calcium gluconate injection, but only 5 companies have submitted supplementary applications for the consistency evaluation of the product, including Hebei Tiancheng Pharmaceutical, Chengdu Bite Pharmaceutical, China Resources Shuanghe Limin, Jiangsu Huayang Pharmaceutical, Yangzhou Zhongbao Pharmaceutical
.
.
The calcium gluconate injection of Chengdu Beite Pharmaceutical Co.
, Ltd.
took the lead in passing the consistency evaluation and became the first company to pass the evaluation, which is conducive to enhancing market competitiveness and expanding market share
.
, Ltd.
took the lead in passing the consistency evaluation and became the first company to pass the evaluation, which is conducive to enhancing market competitiveness and expanding market share
.
Data source: Minet database, CDE
On February 24, NMPA's official website showed that Chengdu Better Pharmaceutical's calcium gluconate injection passed the consistency evaluation of generic drugs, which was the first domestic review
.
Calcium gluconate injection is a commonly used calcium supplement in clinical practice, with terminal sales of over 600 million yuan in Chinese public medical institutions in 2020
.
.
Calcium gluconate injection is a commonly used calcium supplement in clinical practice, with terminal sales of over 600 million yuan in Chinese public medical institutions in 2020
.
Calcium gluconate injection is a commonly used intravenous calcium supplementation drug in clinical practice.
It is suitable for the treatment of calcium deficiency, acute hypocalcemia, alkalosis and tetany caused by hypoparathyroidism
.
It is suitable for the treatment of calcium deficiency, acute hypocalcemia, alkalosis and tetany caused by hypoparathyroidism
.
According to data from Minet.
com, in 2020, the sales of terminal calcium gluconate injection in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 600 million yuan; its sales in the first half of 2021 More than 300 million yuan, a year-on-year increase of 26.
20%
.
com, in 2020, the sales of terminal calcium gluconate injection in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 600 million yuan; its sales in the first half of 2021 More than 300 million yuan, a year-on-year increase of 26.
20%
.
Sales of terminal calcium gluconate injection in Chinese public medical institutions (unit: ten thousand yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
As the main manufacturer of calcium gluconate injection, the market share of this product in Chengdu Bite Pharmaceutical continued to increase.
In 2016, the market share was only 0.
04%, and in the first half of 2021, it has risen to 17.
38%
.
In 2016, the market share was only 0.
04%, and in the first half of 2021, it has risen to 17.
38%
.
At present, a total of 50 domestic companies have the production approval for calcium gluconate injection, but only 5 companies have submitted supplementary applications for the consistency evaluation of the product, including Hebei Tiancheng Pharmaceutical, Chengdu Bite Pharmaceutical, China Resources Shuanghe Limin, Jiangsu Huayang Pharmaceutical, Yangzhou Zhongbao Pharmaceutical
.
.
The calcium gluconate injection of Chengdu Beite Pharmaceutical Co.
, Ltd.
took the lead in passing the consistency evaluation and became the first company to pass the evaluation, which is conducive to enhancing market competitiveness and expanding market share
.
, Ltd.
took the lead in passing the consistency evaluation and became the first company to pass the evaluation, which is conducive to enhancing market competitiveness and expanding market share
.
Data source: Minet database, CDE
On February 24, NMPA's official website showed that Chengdu Better Pharmaceutical's calcium gluconate injection passed the consistency evaluation of generic drugs, which was the first domestic review
.
Calcium gluconate injection is a commonly used calcium supplement in clinical practice, with terminal sales of over 600 million yuan in Chinese public medical institutions in 2020
.
.
Calcium gluconate injection is a commonly used calcium supplement in clinical practice, with terminal sales of over 600 million yuan in Chinese public medical institutions in 2020
.
Calcium gluconate injection is a commonly used intravenous calcium supplementation drug in clinical practice.
It is suitable for the treatment of calcium deficiency, acute hypocalcemia, alkalosis and tetany caused by hypoparathyroidism
.
It is suitable for the treatment of calcium deficiency, acute hypocalcemia, alkalosis and tetany caused by hypoparathyroidism
.
According to data from Minet.
com, in 2020, the sales of terminal calcium gluconate injection in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 600 million yuan; its sales in the first half of 2021 More than 300 million yuan, a year-on-year increase of 26.
20%
.
hospital hospital hospitalcom, in 2020, the sales of terminal calcium gluconate injection in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 600 million yuan; its sales in the first half of 2021 More than 300 million yuan, a year-on-year increase of 26.
20%
.
Sales of terminal calcium gluconate injection in Chinese public medical institutions (unit: ten thousand yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
As the main manufacturer of calcium gluconate injection, the market share of this product in Chengdu Bite Pharmaceutical continued to increase.
In 2016, the market share was only 0.
04%, and in the first half of 2021, it has risen to 17.
38%
.
In 2016, the market share was only 0.
04%, and in the first half of 2021, it has risen to 17.
38%
.
At present, a total of 50 domestic companies have the production approval for calcium gluconate injection, but only 5 companies have submitted supplementary applications for the consistency evaluation of the product, including Hebei Tiancheng Pharmaceutical, Chengdu Bite Pharmaceutical, China Resources Shuanghe Limin, Jiangsu Huayang Pharmaceutical, Yangzhou Zhongbao Pharmaceutical
.
enterprise enterprise enterprise.
The calcium gluconate injection of Chengdu Beite Pharmaceutical Co.
, Ltd.
took the lead in passing the consistency evaluation and became the first company to pass the evaluation, which is conducive to enhancing market competitiveness and expanding market share
.
, Ltd.
took the lead in passing the consistency evaluation and became the first company to pass the evaluation, which is conducive to enhancing market competitiveness and expanding market share
.
Data source: Minet database, CDE
